Physician profile
Anish J Thomas
NPI 1912096231
$170,514.83
in general payments reported to CMS, 2019-2025
40 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $25K · 2021: $30K · 2022: $21K · 2023: $29K · 2024: $26K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $13K · Travel and Lodging: $7,903 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,700 · Honoraria: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,153.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,685.00 |
| Food and Beverage | $12,678.53 |
| Travel and Lodging | $7,903.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,700.00 |
| Honoraria | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51,014.81 | 2019-2024 | Xarelto |
| Abbott Laboratories | $40,452.13 | 2019-2025 | Absolute Pro, Jeti Peripheral Catheter, Esprit |
| Terumo Medical Corporation | $13,246.03 | 2021-2025 | Navicross, Glidewire, Glidesheath Slender |
| Shockwave Medical, INC | $11,526.30 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $11,294.87 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bard Peripheral Vascular, INC. | $9,909.76 | 2021-2024 | |
| Philips North America LLC | $8,518.20 | 2019-2025 | Igt Devices Undivided, (9281) Turbo Elite, (6536) Phoenix |
| Medtronic, INC. | $7,786.45 | 2021-2025 | Abre, Hawkone, Turbohawk |
| Cardiovascular Systems INC. | $6,657.86 | 2019-2022 | |
| Penumbra, INC. | $2,855.08 | 2019-2025 | Benchmark, Penumbra System, Indigo System |
| Abiomed | $1,707.25 | 2019-2025 | Impella |
| Inspiremd LTD | $1,185.59 | 2022-2025 | Cguard, Cguard Prime Carotid Stent System |
| Surmodics, INC. | $750.00 | 2024 | Sublime Microcatheter, 035, 200cm, Angle, Sublime Microcatheter, 018, 200cm, Straight, Sublime 014 Rx Pta Balloon Dilatation Catheter |
| Boston Scientific Corporation | $719.68 | 2019-2025 | General - Crm_crm |
| Medtronic Vascular, INC. | $672.03 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $530.34 | 2019-2025 | Endocross Device, Torus Stent Graft System |
| Cordis US Corp. | $331.50 | 2024-2025 | Mynx Control Venous, S.M.A.R.T. Control |
| Novartis Pharmaceuticals Corporation | $193.41 | 2021-2025 | |
| Vasorum USA INC. | $166.99 | 2023 | Celt Acd |
| Intact Vascular, INC. | $146.38 | 2019 | |
| Reflow Medical INC | $105.41 | 2023-2024 | |
| Pfizer INC. | $102.93 | 2021-2024 | |
| Cardiva Medical, INC. | $87.57 | 2023-2024 | Savvywire, Cardiva Vascade 6/7f Vcs |
| Amgen INC. | $85.24 | 2020-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $70.66 | 2023-2024 | |
| Recor Medical INC | $56.84 | 2025 | Paradise Ultrasound Renal Denervation System |
| Angiodynamics, INC. | $55.21 | 2020 | |
| Janssen Scientific Affairs, LLC | $51.30 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.16 | 2021-2024 | Lifevest |
| Biosense Webster, INC. | $34.25 | 2022 | |
| Merck Sharp & Dohme LLC | $28.27 | 2022-2024 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $25.73 | 2023 | Arcalyst |
| Csl Behring | $20.84 | 2023 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $17.53 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $15.18 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.73 | 2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $13.87 | 2025 | Uptravi, Opsynvi |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.